US EditionPublished • loading... • Updated
Novo Nordisk, Eli Lilly Deny Partnership with Mangoceuticals on Weight-Loss Drugs
Summary by WISH-TV
2 Articles
2 Articles
Novo Nordisk, Eli Lilly deny partnership with Mangoceuticals on weight-loss drugs
(Reuters) — Novo Nordisk and Eli Lilly denied weight-loss drug partnership with Mangoceuticals on Thursday, hours after the telehealth provider disclosed it had arrangements with the two drugmakers. Shares of Mangoceuticals had surged nearly 30% in premarket trading after a press statement from earlier on Thursday said it had partnered with Novo and Lilly to offer blockbuster weight-loss drugs to self-paying patients. Shares closed at $1.19 foll…
·Indianapolis, United States
Read Full Article
Novo Nordisk and Eli Lilly deny: Have not entered into a collaboration with telehealth companyThe news of a collaboration with the giants Novo Nordisk and Eli Lilly sent the telehealth company's stock skyrocketing. Thursday
Coverage Details
Total News Sources2
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
